With multiple countries implementing T1 diabetes screening measures and the concept of early-stage treatment gaining newfound interest in medical circles, DUN T1 is the right therapy developed at the right time.
Company Profile
DUNICA is developing a disruptive therapy for type 1 diabetes that reverses the disease’s progression, delays its onset, and even prevents it altogether. We are utilizing a well-established methodology to extract phytochemicals from a uniquely identified botanical source, refine them, and formulate them into a safe, patient-friendly medication.
Our therapy offers a groundbreaking approach to an autoimmune disease currently deemed incurable. It presents hope for a better life for younger patients, free from restrictive management routines and insulin dependency.
The Time is Now
The year 2022 has brought a significant shift in the traditional conception of T1 diabetes as an incurable disease due to a combination of scientific and systemic changes:
-
Teplizumab (anti-CD3 antibody) was the first drug to be approved by the FDA for delaying the onset of type 1 diabetes before clinical symptoms appear, for patients with stage 2 immune process. Several similar drugs are currently in phase II or III of clinical development.
-
However, most countries and populations will not be able to comply with the administration requirements of the intravenous Teplizumab, which has to be administered over a minimum period of 30 minutes, once daily for 14 days, throughout which the patient must be hospitalized and supervised. For this reason, developing an easy-to-use oral intervention is still an urgent matter.
-
Countries such as the UK, Germany, and Israel have started implementing multiple population-based screening programs for early detection of stage 1 and stage 2 T1 diabetes. Many others are expected to follow their lead as they recognize the importance and scale of this issue. The more patients are diagnosed early, the higher the demand for prevention and cure-oriented solutions - such as ours - will grow.
These changes present a critical window of opportunities for new early-stage T1 diabetes preventative interventions. To succeed, these solutions must address the known challenges of existing diabetes treatments: They should be safe, sustainable, affordable, ideally orally administered, and easy enough to use anywhere in the world without medical supervision, including in developing countries.
We factored all these challenges into DUN T1’s design and production process.
Risk-Mitigating Factors
When considering investing in Dunica, several scientific and regulatory factors should be kept in mind as risk-mitigating aspects:
-
Proven development process
Our development procedure is founded in a well-established method that has been tested and proven safe and effective for years: Isolation of BioActive small molecules. -
Two pathways to final therapy
The unique mechanism of action will allow it to be used both as a lead treatment solo therapy and an add-on to a stem-cell transplant. -
Dedicated regulatory pathway
The FDA has recently set up a dedicated regulatory pathway to approve Early-stage (stage 2) Type 1 Diabetes therapies, which is relatively shorter.
What’s Next?
We are actively seeking partners and investors to collaborate with as we complete the final stages of our pre-clinical phase.
Partner with us to bring our disruptive solution to market and positively impact millions of lives.
Let’s save beta-cells together.